Gossamer Bio(US:GOSS)2025-11-05 22:23Financial Performance - Revenue from contracts with collaborators for Q3 2025 was $13.3 million, compared to $9.5 million for the same period in 2024, representing a 40% increase[12] - Net loss for Q3 2025 was $48.2 million, or $0.21 basic net loss per share, compared to a net loss of $30.8 million, or $0.14 basic net loss per share in Q3 2024[12] - General and Administrative (G&A) expenses for Q3 2025 were $9.4 million, compared to $8.5 million in Q3 2024, reflecting a 10.6% increase[12] - Research and Development (R&D) expenses for Q3 2025 were $45.5 million, up from $34.9 million in Q3 2024, indicating a 30% increase[12] - Total liabilities as of September 30, 2025, were $291.2 million, compared to $285.8 million at the end of 2024[17] - The accumulated deficit increased to $1.39 billion as of September 30, 2025, from $1.27 billion at the end of 2024[17] Cash and Securities - Cash, cash equivalents, and marketable securities totaled $180.2 million as of September 30, 2025[12] Clinical Trials - The PROSERA Phase 3 Study completed enrollment with 390 PAH patients, with topline results expected in February 2026[5] - The SERANATA Phase 3 Study for PH-ILD patients activated its first clinical site in Q4 2025, aiming to enroll approximately 480 patients[8] Strategic Agreements - A strategic option agreement was entered to acquire Respira Therapeutics Inc., with the option to issue 1.5 million shares of Gossamer Bio common stock[8]